Recent Advances in Vitiligo Treatment

Ye Qiu, Xiangxi Su, Jingru Chen, Shaojing Jiang, Xinrui Tang, Yurong He, Fang Liu Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Fang Liu, Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China, Email [email protected]: This review systematically summarizes breakthrough advances in vitiligo treatment from 2020 to 2025 to provide the latest evidence-based insights for clinical practice.Patients and Methods: We searched ClinicalTrials.gov and PubMed for literature and clinical trials published within this period. Inclusion criteria encompassed randomized controlled trials (RCTs), Phase II and above clinical trial results, and fundamental research with clear clinical translational value.Results: Our analysis identified that JAK inhibitors achieved significant repigmentation by blocking the IFN-γ/JAK-STAT signaling pathway, while novel agents such as IL-15 inhibitors selectively eliminated pathogenic CD8⁺ T cells, suppressing immune-mediated damage at its source. The combination of 308 nm excimer laser with JAK inhibitors or platelet-rich plasma (PRP) increased repigmentation rates in acral lesions to 56.1%, and vitamin D adjunct therapy demonstrated synergistic effects. For stable disease, ReCell technology combined with narrowband UVB (NB-UVB) emerged as an effective option, whereas miniature punch grafting further optimized surgical outcomes. Additionally, repurposed traditional drugs and antioxidant strategies expanded the available clinical arsenal.Conclusion: Vitiligo treatment has entered an era of precision immune modulation, with JAK inhibitors establishing themselves as first-line therapy and novel biologics showing significant promise. Combined phototherapy and cellular therapy innovations markedly enhance repigmentation efficiency, and drug repurposing continues to enrich the therapeutic landscape.Keywords: vitiligo, targeted therapy, JAK inhibitors, IL-15 inhibitors, combined phototherapy

Authors

Institutions

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2026-02-01
Primary Topic
melanin and skin pigmentation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recent Advances in Vitiligo Treatment

Jiang Y L Xiang W S, Ji Chen, Yi He, Tang X et al.
SHILAP Revista de lepidopterología
melanin and skin pigmentation
article

Recent Advances in Vitiligo Treatment

Jiang Y L Xiang W S, Ji Chen, Yi He, Tang X, Su X, Liu F, Qiu Y
article en

Abstract

Ye Qiu, Xiangxi Su, Jingru Chen, Shaojing Jiang, Xinrui Tang, Yurong He, Fang Liu Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Fang Liu, Department of Dermatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People’s Republic of China, Email [email protected]: This review systematically summarizes breakthrough advances in vitiligo treatment from 2020 to 2025 to provide the latest evidence-based insights for clinical practice.Patients and Methods: We searched ClinicalTrials.gov and PubMed for literature and clinical trials published within this period. Inclusion criteria encompassed randomized controlled trials (RCTs), Phase II and above clinical trial results, and fundamental research with clear clinical translational value.Results: Our analysis identified that JAK inhibitors achieved significant repigmentation by blocking the IFN-γ/JAK-STAT signaling pathway, while novel agents such as IL-15 inhibitors selectively eliminated pathogenic CD8⁺ T cells, suppressing immune-mediated damage at its source. The combination of 308 nm excimer laser with JAK inhibitors or platelet-rich plasma (PRP) increased repigmentation rates in acral lesions to 56.1%, and vitamin D adjunct therapy demonstrated synergistic effects. For stable disease, ReCell technology combined with narrowband UVB (NB-UVB) emerged as an effective option, whereas miniature punch grafting further optimized surgical outcomes. Additionally, repurposed traditional drugs and antioxidant strategies expanded the available clinical arsenal.Conclusion: Vitiligo treatment has entered an era of precision immune modulation, with JAK inhibitors establishing themselves as first-line therapy and novel biologics showing significant promise. Combined phototherapy and cellular therapy innovations markedly enhance repigmentation efficiency, and drug repurposing continues to enrich the therapeutic landscape.Keywords: vitiligo, targeted therapy, JAK inhibitors, IL-15 inhibitors, combined phototherapy

SHILAP Revista de lepidopterología
Capital Medical University (CN)
Openalex Percentile: Top 60%
melanin and skin pigmentation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Recent Advances in Vitiligo Treatment — Jiang Y L Xiang W S, Ji Chen, et al. · SHILAP Revista de lepidopterología (2026) | TGRS Research Map | TGRS